Translate Bio, Inc. (TBIO): Price and Financial Metrics


Translate Bio, Inc. (TBIO): $37.36

-0.05 (-0.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TBIO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 506

in industry

TBIO POWR Grades


  • Quality is the dimension where TBIO ranks best; there it ranks ahead of 93.17% of US stocks.
  • TBIO's strongest trending metric is Momentum; it's been moving down over the last 47 weeks.
  • TBIO's current lowest rank is in the Stability metric (where it is better than 3.27% of US stocks).

TBIO Stock Summary

  • Translate Bio Inc's stock had its IPO on June 28, 2018, making it an older stock than merely 9.36% of US equities in our set.
  • With a year-over-year growth in debt of 367.71%, Translate Bio Inc's debt growth rate surpasses 97.18% of about US stocks.
  • As for revenue growth, note that TBIO's revenue has grown 761.44% over the past 12 months; that beats the revenue growth of 98.72% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Translate Bio Inc are ALPN, SELB, DTIL, FULC, and ANAB.
  • Visit TBIO's SEC page to see the company's official filings. To visit the company's web site, go to www.translate.bio.

TBIO Valuation Summary

  • In comparison to the median Healthcare stock, TBIO's EV/EBIT ratio is 125.94% higher, now standing at 66.2.
  • Over the past 39 months, TBIO's price/sales ratio has gone NA NA.
  • TBIO's price/earnings ratio has moved up 76.6 over the prior 39 months.

Below are key valuation metrics over time for TBIO.

Stock Date P/S P/B P/E EV/EBIT
TBIO 2021-08-31 12.6 6.9 69.9 66.2
TBIO 2021-08-30 12.6 6.9 70.0 66.3
TBIO 2021-08-27 12.5 6.8 69.6 65.9
TBIO 2021-08-26 12.4 6.8 68.9 65.3
TBIO 2021-08-25 12.4 6.8 69.2 65.5
TBIO 2021-08-24 12.7 6.9 70.5 66.9

TBIO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TBIO has a Quality Grade of B, ranking ahead of 93.17% of graded US stocks.
  • TBIO's asset turnover comes in at 0.251 -- ranking 176th of 677 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows TBIO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.251 1 0.100
2021-03-31 0.215 1 -0.047
2020-12-31 0.217 1 -0.366
2020-09-30 0.182 1 -0.862
2020-06-30 0.072 1 -1.159
2020-03-31 0.034 1 -0.925

TBIO Price Target

For more insight on analysts targets of TBIO, see our TBIO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.57 Average Broker Recommendation 1.81 (Hold)

TBIO Stock Price Chart Interactive Chart >

Price chart for TBIO

TBIO Price/Volume Stats

Current price $37.36 52-week high $37.99
Prev. close $37.36 52-week low $11.91
Day low $37.16 Volume 1,352,300
Day high $37.64 Avg. volume 1,660,263
50-day MA $34.70 Dividend yield N/A
200-day MA $24.81 Market Cap 2.82B

Translate Bio, Inc. (TBIO) Company Bio


Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is based in Lexington, Massachusetts.


TBIO Latest News Stream


Event/Time News Detail
Loading, please wait...

TBIO Latest Social Stream


Loading social stream, please wait...

View Full TBIO Social Stream

Latest TBIO News From Around the Web

Below are the latest news stories about Translate Bio Inc that investors may wish to consider to help them evaluate TBIO as an investment opportunity.

Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today reported that on September 8, 2021, the Company granted restricted stock units for an aggregate of 54,078 shares of the Company’s common stock to twenty new employees. These grants were made pursuant to the Company’s 2021 Indu

Yahoo | September 8, 2021

'It's game over. It's mRNA or nothing:' Expert on future of vaccines

mRNA technology has taken the world by storm thanks to the success of two vaccine companies in 2020. What lies ahead?

Yahoo | September 7, 2021

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates TGRF, SIC, SAFM, TBIO; Shareholders are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / August 26, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:TGR Financial, Inc. (OTCQX:TGRF) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to First Foundation Inc.

Yahoo | August 26, 2021

SHAREHOLDER ALERT: WeissLaw LLP Reminds PFOH, TBIO, LDL, and SNR Shareholders About Its Ongoing Investigations

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Yahoo | August 24, 2021

Pilgrim’s Pride and Icosavax See Activist Action

JBS Brazil offered to buy the rest of poultry-producer Pilgrim’s Pride. RA Capital disclosed a large position in biotech Icosavax.

Yahoo | August 20, 2021

Read More 'TBIO' Stories Here

TBIO Price Returns

1-mo -0.82%
3-mo 103.49%
6-mo 127.11%
1-year 153.29%
3-year 260.97%
5-year N/A
YTD 102.71%
2020 126.41%
2019 8.53%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.298 seconds.